Table 3.
Demographic and clinical characteristics of 210 AF patients with thyroid disorders with reference to thyroid status.
| Clinical feature | AF/Hypothyroidism n (%) | AF/Hyperthyroidism n (%) | AF/Euthyroid n (%) | p-value | |
|---|---|---|---|---|---|
| Age in years (mean ± SD) | 70.0 ± 11.0 | 70.5 ± 11.6 | 67.1 ± 9.0 | .779 | |
| Gender | .029 | ||||
| Male | 44 (20.9%) | 7 (3.3%) | 3 (1.4%) | ||
| Female | 146 (69.5%) | 6 (2.8%) | 4 (1.9%) | ||
| Medical History | |||||
| Hypertension | 145 (69.0%) | 10 (4.7%) | 3 (1.4%) | .130 | |
| Diabetes Mellitus | 95 (45.2%) | 8 (3.8%) | 4 (1.9%) | .684 | |
| Dyslipidemia | 85 (40.4%) | 9 (4.2%) | 2 (0.9%) | .150 | |
| Currently smokers | 12 (5.7%) | 3 (1.4%) | 1 (0.4%) | .070 | |
| BMI | .132 | ||||
| X ≥ 24.9 | 32 (15.2%) | 4 (1.9%) | 2 (0.9%) | ||
| 25 > X > 29.9 | 48 (22.8%) | 5 (2.3%) | 4 (1.9%) | ||
| X ≥ 30 | 87 (41.4%) | 3 (1.4%) | 1 (0.4%) | ||
| Type of AF | .593 | ||||
| Paroxysmal | 64 (30.4%) | 6 (2.8%) | 3 (1.4%) | ||
| Non-paroxysmal | 126 (60.0%) | 7 (3.3%) | 4 (1.9%) | ||
| Etiology of AF | .277 | ||||
| Valvular | 19 (9.0%) | 3 (1.4%) | 1 (0.4%) | ||
| Non-valvular | 171 (81.4%) | 10 (3.3%) | 6 (2.8%) | ||
| AF symptoms | |||||
| Palpitations | 80 (38.0%) | 7 (3.3%) | 2 (0.9%) | .535 | |
| SOB | 77 (36.6%) | 7 (3.3%) | 2 (0.9%) | .509 | |
| Fatigue | 54 (25.7%) | 4 (1.9%) | 2 (0.9%) | .984 | |
| Dizziness | 29 (13.8%) | 3 (1.4%) | 0 (0.0%) | .391 | |
| Syncope | 7 (3.3%) | 1 (0.4%) | 0 (0.0%) | .664 | |
| Chest pain | 2 (0.9%) | 1 (0.4%) | 1 (0.4%) | .012 | |
| Asymptomatic | 52 (24.7%) | 4 (1.9%) | 3 (1.4%) | .645 | |
| Comorbid diseases | |||||
| Stroke or systemic embolization | 31 (16.6%) | 2 (0.9%) | 2 (0.9%) | .539 | |
| Heart failure | 41 (19.5%) | 4 (1.9%) | 2 (0.9%) | .687 | |
| Left ventricular hypertrophy | 65 (30.9%) | 3 (1.4%) | 3 (1.4%) | .850 | |
| Coronary artery disease | 11 (5.2%) | 1 (0.4%) | 2 (0.9%) | .059 | |
| Congenital heart disease | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) | .948 | |
| Pulmonary hypertension | 68 (32.3%) | 2 (0.9%) | 2 (0.9%) | .308 | |
| Sleep apnea | 10 (4.7%) | 0 (0.0%) | 0 (0.0%) | .575 | |
| Chronic kidney disease | 27 (12.8%) | 1 (0.4%) | 1 (0.4%) | .804 | |
| Active malignancy | 10 (4.7%) | 0 (0.0%) | 0 (0.0%) | .575 | |
| CHA2DS2-VASc score | .387 | ||||
| Score 1 in women and 0 in men (1) | 11 (5.2%) | 1 (0.4%) | 0 (0.0%) | ||
| Score 2 in women and 1 in men (2) | 21 (10.0%) | 0 (0.0%) | 2 (0.9%) | ||
| Score ≥ 3 in women and ≥ 2 in men (3) | 158 (75.2%) | 12 (5.7%) | 5 (2.3%) | ||
| HAS-BLED score | .693 | ||||
| 0 | 25 (11.9%) | 2 (0.9%) | 0 (0.0%) | ||
| 1 | 68 (32.3%) | 2 (0.9%) | 2 (0.9%) | ||
| 2 | 60 28.5%) | 6 (2.8%) | 3 (1.4%) | ||
| ≥ 3 | 37 (17.6%) | 3 (1.4%) | 2 (0.9%) | ||
| Echocardiography findings | |||||
| LVEF (mean ± SD) | 54.8 ± 12.3 | 53.8 ± 19.6 | 49.1 ± 14.0 | .503 | |
| Moderate to severe rhematic mitral stenosis | 7 (3.3%) | 2 (0.9%) | 0 (0.0%) | .112 | |
| Metallic prosthetic valve | 12 (5.7%) | 1 (0.4%) | 1 (0.4%) | .700 | |